Therapeutic Asset Ratings

Autologous T Cells Obtained From Peripheral Blood Mononuclear Cells By Leukapheresis, Transduced With A Self-Inactivating, Nonreplicating Lentiviral Vector, Encoding A T Cell Chimeric Antigen Receptor Targeting Cd19. The Expressed Transgene Comprises A Cd8? Leader Sequence, A Murine Anti-Cd19 Single Chain Variable Fragment (Scfv) Derived From The Mouse Hybridoma Fmc63, A Cd8? Hinge And Transmembrane Region, And A 4-1Bb (Cd137) And Cd3? (Tcr?) Signaling Domain And Is Under Control Of The Elongation Factor 1 Alpha (Ef1?) Promoter. The Construct Is Flanked By 5' And 3' Long Terminal Repeats (Ltrs) And Also Contains A ? Packaging Signal, A Rev Response Element (Rre), A Central Polypurine Tract (Cppt) Sequence And An Optimized Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (Wpre). The Leukapheresis Material Is Enriched For Cd4/Cd8 T Cells By Positive Immunoselection, Activated By Cd3 And Cd28 Agonists And Transduced With The Vector. Without Further Cell Propagation, The T Cells Are Washed, Formulated For Infusion, And Cryopreserved. The Substance Is Composed Of ?80% T Cells And ?1% B Cells, With A Mixture Of Transgene Positive (>3.4%) And Negative T Cells. The Cd4+ And Cd8+ Naïve T Cell Subsets (Cd45Ra+Ccr7+) Present In The Leukapheresis Material Are Largely Retained

Avelumab

Avelumab

Avelumab

Avutometinib

Avutometinib

Avutometinib

Avutometinib

Avzo-021

Avzo-023

Avzo-103

Avzo-1418

Avzo-1418

Axitinib

Azacitidine

azd4512

azd5492

azd6750

azd8421

Bafisontamab

Balstilimab

Balstilimab

Balstilimab

bat1308

bat8008